Until very recently, people looking to lose weight had limited options open to them. You could take a pill, such as orlistat , or in some cases you might be eligible for bariatric surgery. But for the most part, you were expected to rely on diet and exercise alone. And as study after study has shown, that isn’t always a solution for long-term weight loss.
The introduction of drugs like Mounjaro, Wegovy and Saxenda has radically changed this picture. For the first time, people are being prescribed injectable medications that have been clinically shown to make a real difference. Less drastic than bariatric surgery, and more effective than orlistat, these types of drugs are associated with a weight loss of 10% or more.
These drugs (known as GLP-1 receptor agonists) are a type of peptide. Collectively, peptides represent an important new approach in weight management. In this article, we’ll demystify what peptides are and how some types can help with weight loss.
What are peptides?
Peptides are short strings of amino acids, the building blocks that come together to make up proteins. There are many different types of peptides, all of which play different roles in the body. For instance, peptides form the basis of hormones like insulin and oxytocin. Others play a role in the immune system or are involved in signalling between cells.
Therapeutic peptides are peptides used for medical purposes. They are either extracted from living organisms, where they naturally occur, or made in the lab. They’ve been around for a while—the first therapeutic peptide was insulin, used to treat diabetes, which was first extracted more than 100 years ago.
Since then, more than 80 therapeutic peptides have been approved for use, and at least twice that number are in clinical development. These drugs are used to treat everything from HIV to septic shock to erectile dysfunction. They may be safer than other types of drug, because they’re good at reaching the places they need to in the body, and their byproducts are generally non-toxic. Weight loss drugs are a new type of therapeutic peptide.
Understanding peptides and their role in weight management
The new peptide drugs for weight loss (Wegovy, Saxenda and Mounjaro) are GLP-1 receptor agonists. That means they work by mimicking glucagon-like peptide 1 (GLP-1), a peptide hormone produced in the gut after meals. GLP-1 plays several important roles in the body:
- It stimulates the pancreas to release insulin after meals, which helps to move glucose (sugar) out of the blood and into the cells.
- It blocks the release of another hormone called glucagon, which works the opposite way to insulin.
- It interacts with various brain regions to reduce appetite and regulate digestion.
- It slows down the rate of gastric (stomach) emptying.
- It plays a role in reducing food cravings and ‘food noise’ (you spend less time thinking about food).
Weight loss peptide drugs contain molecules that are structurally very similar to the GLP-1 hormone. That means they bind to GLP-1 receptors in the gut, pancreas and brain, a bit like a key opening a lock. They unleash the same effects as the actual hormone would.
Mounjaro also works by mimicking another hormone, glucose-dependent insulinotropic polypeptide (GIP), which works in a similar way to GLP-1.
Types of peptides used for weight loss
Three peptide drugs are available for weight management in the UK:
Wegovy
Wegovy contains the active ingredient semaglutide, which works by mimicking a peptide hormone called GLP-1. It’s a once-weekly injection.
Saxenda
Saxenda contains the active ingredient liraglutide, which also mimics GLP-1. Although it’s very similar to semaglutide, it doesn’t last as long in the body, so you need to inject it every day.
Mounjaro
Mounjaro contains the active ingredient tirzepatide, which works by mimicking the peptide hormones GLP-1 and GIP. Like semaglutide, it’s a once-weekly injection.
Efficacy of peptide therapies in weight loss
In clinical studies, peptide therapies have been shown to be very effective for weight loss:
In one trial , participants taking Mounjaro lost an average of 22.5% of their starting body weight in 72 weeks.
In another trial , people taking Wegovy lost an average of almost 15% in 68 weeks.
These drugs have been shown to have benefits beyond weight loss too:
Improving heart health
In one large study , people with cardiovascular conditions took semaglutide for four years. Regardless of how much weight they lost, they cut their risk of heart attacks, stroke, or other life-threatening heart events by 20%.
Improving brain health
Another study found that people taking these drugs had a lower risk of Alzheimer’s disease.
Reducing blood pressure
In another study , people taking tirzepatide saw meaningful reductions in their systolic blood pressure—up to 10.6 mmHg depending on the dose.
Reducing the risk of kidney or liver disease
These drugs have been found to reduce the risk of kidney failure by 16%. And although more research is needed, they may also have the potential to treat fatty liver disease.
Safety profile and potential side effects
Because all three peptide injections for weight loss work in a similar way, they are associated with similar side effects :
- Gastrointestinal side effects (burping, flatulence, constipation, diarrhoea, nausea and vomiting)
- Stomach pain
- Tiredness
- Dizziness
- Injection site reactions like irritation, itching and bruising.
These side effects are usually mild and manageable, and will clear up by themselves as your body gets used to the medication. But it’s important to take the drugs under medical supervision to minimise the risks. You should also make sure you’re living a healthy lifestyle, to give your body the best chance of responding the way it should.
Considerations for use
Peptide therapies for weight loss are a good option for many people who are struggling to lose weight through other means. To receive a private prescription for these drugs, you need to have a body mass index (BMI) of 30 or more, or a BMI of 27 or more along with at least one weight-related health condition.
But there are certain circumstances in which they won’t be suitable for you, for instance if you’re pregnant or breastfeeding, or if you’re living with certain medical conditions.
That’s why these drugs aren’t available over-the-counter—you need a prescription from a healthcare provider who can tailor your treatment to your individual needs. Since it’s important to follow specific dosing guidelines, and monitor for side effects, your relationship with that clinician should be ongoing. They will support you at every step of the way.
Could peptide drugs help kickstart your weight loss journey?
Peptide drugs are not a silver bullet for fat loss, and you’re unlikely to see dramatic effects straight away. That said, they can be very effective over the long term, as part of a treatment plan incorporating lifestyle changes. Why not spend a few minutes answering these questions to see if they might be right for you?
Frequently asked questions (FAQs)
Do peptides for weight loss really work?
Yes. They don’t work for everyone, and results will vary from one person to the next. But most people can expect to see significant weight loss on peptide drugs.
Can I use peptides every day?
If you’re taking peptide therapies for weight loss, you will be experiencing their benefits every day. But Mounjaro and Wegovy are administered just once a week. Only Saxenda requires a daily injection.
What is the best peptide for weight loss?
Mounjaro has the most impressive clinical results, followed by Wegovy. But what’s best for you will depend on your clinician’s recommendation. Here’s what you need to know if you’re thinking about switching from Wegovy to Mounjaro.
Do you need a prescription for peptides for weight loss?
Yes. These drugs aren’t suitable for everyone, so it’s important to take them under the guidance of a healthcare provider.
How long do you need to take peptide therapies for weight loss?
It’s a long-term journey. Studies have found that it takes more than a year to reach peak weight loss, and you may need to be on the drugs for longer than that to maintain the benefits.
How fast do peptides help you lose weight?
The medications will start working as soon as they’re in your body, but everyone sees results at different rates . On average , people have lost around 2% of their starting weight at four weeks. At Voy, we would expect individuals to lose at least 10% of their initial weight within six months alongside coaching support.
Who should consider peptides for weight loss?
If you’re overweight and struggling to lose weight by other means, peptides might be a really good solution. But always talk to your healthcare provider to check whether they’re right for you.
Published: 10th February 2025
¹Badve, Sunil V., et al. “Effects of GLP-1 Receptor Agonists on Kidney and Cardiovascular Disease Outcomes: A Meta-analysis of Randomised Controlled Trials.” The Lancet Diabetes & Endocrinology
, Nov. 2024, https://doi.org/10.1016/s2213-8587(24)00271-7.
²De Lemos, James A., et al. “Tirzepatide Reduces 24-Hour Ambulatory Blood Pressure in Adults With Body Mass Index ≥27 Kg/M²: SURMOUNT-1 Ambulatory Blood Pressure Monitoring Substudy.” Hypertension, vol. 81, no. 4, Feb. 2024, https://doi.org/10.1161/hypertensionaha.123.22022.
³Ge, Long, et al. “Comparison of Dietary Macronutrient Patterns of 14 Popular Named Dietary Programmes for Weight and Cardiovascular Risk Factor Reduction in Adults: Systematic Review and Network Meta-analysis of Randomised Trials.” BMJ, Apr. 2020, p. m696. https://doi.org/10.1136/bmj.m696.
⁴Hayashi, Daisuke, et al. “What Is Food Noise? A Conceptual Model of Food Cue Reactivity.” Nutrients, vol. 15, no. 22, Nov. 2023, p. 4809. https://doi.org/10.3390/nu15224809.
⁵Jastreboff, Ania M., et al. “Tirzepatide Once Weekly for the Treatment of Obesity.” New England Journal of Medicine, vol. 387, no. 3, June 2022, pp. 205–16. https://doi.org/10.1056/nejmoa2206038.
⁶Kommu, Sharath, and Philip Whitfield. “Semaglutide.” StatPearls - NCBI Bookshelf, 11 Feb. 2024, www.ncbi.nlm.nih.gov/books/NBK603723.
⁷Lin, Fei, et al. “Weight Loss Efficiency and Safety of Tirzepatide: A Systematic Review.” PLoS ONE, vol. 18, no. 5, May 2023, p. e0285197. https://doi.org/10.1371/journal.pone.0285197.
⁸Lincoff, A. Michael, et al. “Semaglutide and Cardiovascular Outcomes in Obesity Without Diabetes.” New England Journal of Medicine, vol. 389, no. 24, Nov. 2023, pp. 2221–32. https://doi.org/10.1056/nejmoa2307563.
⁹“Liraglutide Side Effects.” NICE, bnf.nice.org.uk/drugs/liraglutide/#side-effects. Accessed 30 Jan 2025.
¹⁰“MHRA Reminds Healthcare Professionals to Advise Patients of the Side Effects of GLP-1 Agonists and to Report Misuse.” Medicines and Healthcare products Regulatory Agency, 23 Oct. 2024, www.gov.uk/government/news/mhra-reminds-healthcare-professionals-to-advise-patients-of-the-side-effects-of-glp-1-agonists-and-to-report-misuse.
¹¹“Peptide.” Genome.gov, www.genome.gov/genetics-glossary/Peptide. Accessed 30 Jan 2025.
¹²Rossino, Giacomo, et al. “Peptides as Therapeutic Agents: Challenges and Opportunities in the Green Transition Era.” Molecules, vol. 28, no. 20, Oct. 2023, p. 7165. https://doi.org/10.3390/molecules28207165.
¹³Rubino, Domenica M., et al. “Effect of Weekly Subcutaneous Semaglutide Vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes.” JAMA, vol. 327, no. 2, Jan. 2022, p. 138. https://doi.org/10.1001/jama.2021.23619.
¹⁴Ryan, Donna, et al. “Long-term Weight Loss Effects of Semaglutide in Obesity Without Diabetes in the SELECT Trial.” Nature Medicine, vol. 30, no. 7, May 2024, pp. 2049–57. https://doi.org/10.1038/s41591-024-02996-7.
¹⁵“Semaglutide Side Effects.” NICE, bnf.nice.org.uk/drugs/semaglutide/#side-effects. Accessed 30 Jan 2025.
¹⁶“Tirzepatide Side Effects.” NICE, bnf.nice.org.uk/drugs/tirzepatide/#side-effects. Accessed 30 Jan 2025.
¹⁷Wang, Lei, et al. “Therapeutic Peptides: Current Applications and Future Directions.” Signal Transduction and Targeted Therapy, vol. 7, no. 1, Feb. 2022, https://doi.org/10.1038/s41392-022-00904-4.
¹⁸Xie, Yan, et al. “Mapping the Effectiveness and Risks of GLP-1 Receptor Agonists.” Nature Medicine, Jan. 2025, https://doi.org/10.1038/s41591-024-03412-w.
¹⁹Zhu, Kai, et al. “Efficacy and Safety of Semaglutide in Non-alcoholic Fatty Liver Disease.” World Journal of Gastroenterology, vol. 29, no. 37, Sept. 2023, pp. 5327–38. https://doi.org/10.3748/wjg.v29.i37.5327.
